The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Am J Psychiatry 163:1451, August 2006
doi: 10.1176/appi.ajp.163.8.1451
© 2006 American Psychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by HILLEMACHER, T.
* Articles by FRIELING, H.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by HILLEMACHER, T.
* Articles by FRIELING, H.
Related Collections
* Other Treatment

Letter to the Editor

Hair Loss as a Side Effect of Lamotrigine Treatment

THOMAS HILLEMACHER, M.D., STEFAN BLEICH, M.D., JOHANNES KORNHUBER, M.D., and HELGE FRIELING, M.D.
Erlangen, Germany

To the Editor: Lamotrigine is an established and usually well tolerated treatment for bipolar disorder. Adverse effects of the drug may include serious toxic epidermal necrolysis, in which alopecia is a well known phenomenon (1). However, apart from occurring as a part of epidermal necrolysis, hair loss is usually not associated with lamotrigine treatment in the literature (2).

"Mrs. G," a 63-year-old woman, was treated as an inpatient from Aug. to Sept. 2003 because of a depressive episode from a previously diagnosed bipolar disorder. During hospitalization, therapy with lamotrigine was started, and the dose was later increased in an ambulant setting up to 150 mg daily. After her discharge, Mrs. G was visited regularly by the psychiatric ambulance. During this entire period, she did not receive any other pharmaceutical treatment except eye drops containing hypromellose. She reported an increase in hair loss 2 to 3 weeks after beginning lamotrigine treatment. The hemogram and other laboratory parameters did not show pathological findings. The result of the trichogram, a classical hair root examination made by an external consultant dermatologist in Nov. 2003, showed an increase of resting (telogen) and dystrophic hair at the expense of growing (anagen) hair. The hair loss was mainly located in the area of the temporal bone, which is characteristic for pharmacologically induced alopecia (3, 4).

Because of the probable association of the reported alopecia with lamotrigine treatment, the treatment was discontinued, which resulted in a rapid regression of hair loss.

Hair loss has been reported as a rare side effect of lamotrigine treatment in the German Summary of Product Characteristics. However, in the literature (using MEDLINE, PubMed, ISIweb, and Embase research) we only found one case report suggesting a possible link between hair loss and lamotrigine treatment (5). Patrizi and colleagues reported a case of a patient who was treated with a combination of magnesium valproate and lamotrigine and suffered from hair loss. The authors indicate that the hair loss in their patient may have been caused by the intake of magnesium valproate (5).

To our knowledge, our case is the first report of a causal connection between lamotrigine intake and alopecia. Our patient had not been treated with medications other than lamotrigine, and the pathology vanished after discontinuation of the drug, which makes a coincidence unlikely. Patients and clinicians should be aware of alopecia as a possible rare side effect of lamotrigine treatment.

References

  1. Sullivan JR, Watson A: Lamotrigine-induced toxic epidermal necrolysis treated with intravenous cyclosporin: a discussion of pathogenesis and immunosuppressive management. Australas J Dermatol 1996; 37:208–212[Medline]
  2. Mercke Y, Sheng H, Khan T, Lippmann S: Hair loss in psychopharmacology. Ann Clin Psychiatry 2000; 12:35–42[CrossRef][Medline]
  3. Harrison S, Sinclair R: Telogen effluvium. Clin Exp Dermatol 2002; 27:389–395[CrossRef][Medline]
  4. Brodin MB: Drug-related alopecia. Dermatol Clin 1987; 5:571–579[Medline]
  5. Patrizi A, Savoia F, Negosanti F, Posar A, Santucci M, Neri I: Telogen effluvium caused by magnesium valproate and lamotrigine. Acta Derm Venereol 2005; 85:77–78[CrossRef][Medline]



This article has been cited by other articles:


Home page
Am. J. PsychiatryHome page
D. H. BARZMAN and M. P. DelBello
Drs. Barzman and DelBello Reply
Am J Psychiatry, March 1, 2007; 164(3): 527 - 528.
[Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
S. P. KRUSZEWSKI and S. G. KLOTZ
Effects of Topiramate
Am J Psychiatry, March 1, 2007; 164(3): 526 - 527.
[Full Text] [PDF]


This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by HILLEMACHER, T.
* Articles by FRIELING, H.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by HILLEMACHER, T.
* Articles by FRIELING, H.
Related Collections
* Other Treatment


Get information about faster international access.

Privacy Policy

Copyright © 2006 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org